Americans struggling with obesity now have a powerful new treatment option: Zepbound (tirzepatide), a next-generation weight loss drug developed by Eli Lilly, is now available from Canada through the online pharmacy fulfilment platform Duty Free Meds.
Originally launched in the United States, Zepbound quickly gained attention for its unprecedented efficacy in clinical trials. With Health Canada’s recent approval, Americans can now access the medication more affordably, without relying on traditional pharmacy channels that may face supply constraints or markups.
“We’re proud to provide Americans with affordable access to Zepbound,” said Hank Popeil, spokesperson for DutyFreeMeds.com. “With rising demand and limited availability through traditional channels, our platform plays a key role in making this important treatment more accessible.”
Why Is Zepbound a Game-Changer?
Zepbound works by activating two key gut hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual-action mechanism helps suppress appetite, regulate insulin, and promote significant weight loss. In Eli Lilly’s SURMOUNT-1 Phase 3 clinical trial, patients lost an average of up to 22.5% of their body weight after 72 weeks of treatment with the highest dose of tirzepatide (NEJM, 2022).
“This level of weight loss is comparable to what we typically see after bariatric surgery,” said Dr. Robert Kushner, lead author of the SURMOUNT-1 trial and Professor of Medicine at Northwestern University Feinberg School of Medicine. “It’s a major leap forward in the treatment of obesity.”
Zepbound is part of a growing class of drugs known as incretin mimetics, which includes medications like Ozempic (semaglutide). But what sets tirzepatide apart is its dual-agonist approach, which experts say offers enhanced metabolic benefits over single-agonist therapies.
Access and Affordability: DutyFreeMeds.com Steps In
While Zepbound’s U.S. retail price can exceed $1,000 per month without insurance, DutyFreeMeds.com offers the medication at significantly reduced prices. The company sources medications from licensed international pharmacies, ensuring safety and efficacy while removing unnecessary markups.
This price transparency is especially important as patients across America increasingly seek alternatives to domestic pricing models.
“Too many patients are priced out of life-changing treatments,” said Dr. Yoni Freedhoff, a Canadian obesity expert and associate professor at the University of Ottawa. “Improved accessibility, especially through regulated international providers, is a step in the right direction.”
Based in Manitoba, DutyFreeMeds.com works with certified healthcare professionals to ensure that all medications meet Health Canada standards. Their fulfillment process emphasizes safety, quality, and convenience, and thousands of American patients rely on the service for secure delivery.
A Broader Shift in Obesity Care
Zepbound’s approval in Canada marks a broader shift in how obesity is treated and perceived. Once viewed purely as a lifestyle issue, obesity is now increasingly recognized as a complex metabolic condition requiring long-term medical management.
“We now understand that obesity is not simply a matter of willpower,” said Dr. Arya Sharma, founding chair of the Canadian Obesity Network. “Medications like Zepbound allow us to treat it more effectively and reduce associated health risks.”
As new treatments emerge and platforms like DutyFreeMeds.com make them more accessible to American patients in the USA, patients may finally begin to see real progress in managing chronic weight-related conditions.
Final Thoughts
With Zepbound now available in the USA from Canada via DutyFreeMeds.com, the future of obesity care is looking more hopeful. As awareness, innovation, and accessibility continue to improve, Americans are gaining new tools to take control of their health.
To learn more about Zepbound and explore available options, visit www.dutyfreemeds.com.
